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Editorial on the Research Topic
Diacylglycerol Kinase Signalling
By gathering 10 reviews from leading scientists in a fast-evolving field, this Research Topic
illustrates the contribution of diacylglycerol kinase (DGK) family members to the regulation of
cell responses, and how their malfunction contributes to human pathologies.
DGK transform diacylglycerol (DG) into phosphatidic acid (PA). This simple reaction alters
the levels of two lipids with central functions as second messengers, as phospholipid precursors,
and as membrane modulators. The first DGK was purified and cloned by the Hideo Kanoh group
in 1990; since then, the study of DGK regulation and functions has expanded and grows daily.
Mammalian DGK comprise 10 isoforms that are particularly abundant in brain and hematopoietic
organs. Not surprisingly, DAG effectors such as protein kinase C family members, mammalian
Unc13 homologs, the chimaerin family of Rac GTPases, and the Ras GEF RasGRPs have critical
functions in the regulation of nervous and immune synapses.
The mammalian DGK isoforms are grouped into five subtypes based on the presence of distinct
regulatory domains. At least eight DGK isoforms are detected in the mammalian brain. In their
review, Lee et al. summarize studies that link various DGK isoforms with certain features of
synaptic plasticity. The generation of knockout mice for specific DGK isoforms has demonstrated
their involvement in distinct aspects of brain function. These findings imply precise, isoform-
specific control of lipid homeostasis that creates local environments suitable for triggering synaptic
plasticity. Genome-wide association studies suggest relationships between specific DGK and
human diseases that include bipolar disease and Parkinson’s disease. Sakane et al. review these
findings and discuss others such as mutations in the DGKE gene and its link to epilepsy and
Huntington disease, or the more recent discovery of DGKE mutations associated with atypical
hemolytic-uremic syndrome (aHUS).
The predominance of DGKε malfunction and disease might be related to this isoform’s unique
properties. DGKε is the only DGK familymember that lacks regulatory domains, that ismembrane-
bound, and has substrate specificity for arachidonate-containing DG. Two articles in this series
review DGKε properties and functions in depth, and cast new light on the links between DGKε
defects and disease. Epand et al. describe the structural features that lend DGKε its arachidonoyl-
DG specificity, its regulation by phosphorylation, and the identification of DGKε-interacting
proteins. They discuss at length the unanticipated connection between recessive DGKE mutations
and aHUS, recently uncovered by whole-exome sequencing. Although dysregulated complement
activation is generally associated with all aHUS forms, the vast majority of aHUS patients that
harbor DGKE mutations do not show this defect. DGKε is found at the endoplasmic reticulum
(ER), a specialized site in membrane phospholipid synthesis and transport. In their review, Nakano
et al. discuss the DGKε-specific contribution at the ER by generating arachidonoyl PA that
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feeds directly into the PI cycle. DGKε malfunction impairs PA
generation and facilitates DG lipase-dependent DG degradation
to 2-arachidonoyl glycerol, an endocannabinoid with important
contributions to retrograde synaptic transmission.
All 10 mammalian DGK isoforms share a conserved catalytic
domain and two protein kinase C conserved type I (C1) domains.
The exception, with three C1 domains, is DGKθ, the lone
member of the type V DGK class and the least-studied. In
their detailed review, Tu-Sekine et al. cover DGKθ structure,
enzymology and the latest results, which suggest its contribution
to regulation of neurotransmission.
In addition to this notable role in brain, the DGK contribution
to immune response control is another area of intensive
research. T lymphocyte recognition of antigens presented on the
antigen-presenting cell surface generates a polarized increase in
membrane DG at the contact area. Sustained DG generation at
the immune synapse facilitates activation of the Ras/ERK and
PKC pathways, which ultimately dictate the fate of differentiated
T cell populations. Chen et al. extensively describe the studies
with DGKα- and ζ -deficient mice that have defined the
contribution of these two isoforms to differentiation of CD8 T
effector and memory populations, development of regulatory T
cells (Treg), and lineage development of invariant natural killer
cells. At difference from DGKα, expressed predominantly in T
cells, DGKζ is expressed ubiquitously in hematopoietic cells.
Singh and Kambayashi’s review explores the immunomodulatory
function of DGKζ in several cell types. The dual contribution of
DGKζ , which can either potentiate or limit immune responses,
adds new interest to its targeting. In addition to promoting
defense against infection or cancer, DGKζ inhibition might have
benefits by limiting immune responses in pathological conditions
such as allergy and septic shock.
Due to their negative regulatory T cell function, DGKα and
ζ have recently attracted interest as prospective targets, which
might improve T cell-mediated tumor destruction. Two articles
in this series examine the findings from their own and other
groups that identify DGKα and ζ targeting potential in the fight
against cancer. The contribution of DGKα as a cytosolic immune
checkpoint is detailed reviewed in Noessner. On their review,
Riese et al. consider DGKα and ζ contributions to limiting anti-
tumor functions of engineered cytotoxic T cells. In both cases,
pharmacological DGKα inhibitors induce recovery of cytotoxic
functions by tumor-infiltrating cells, although the precise role of
each isoform and the consequences of specific DGK ζ inhibition
remain to be addressed. The continued search for new, more
effective DGK inhibitors is a critical issue that is addressed by
Sakane’s group, who review the recent characterization of a new
DGKα inhibitor.
DGK phosphorylation of DAG to PA is the principal pathway
of DAG signaling termination. Through PA generation, DGK
enzymes promote local alteration of membrane composition and
electrostatic charge, which leads to recruitment and activation
of additional sets of proteins. Baldanzi et al. illustrate how PA
generation in specific membrane subdomains affects polarized
responses such as immune synapse formation or cell migration.
We are deeply indebted to all the authors who have
contributed to this Research Topic and to the dedicated reviewers
who helped us achieve the highest quality standards. We
gratefully acknowledge the valuable support of the Frontiers team
in manuscript processing.
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